Legato Capital Management’s Haemonetics HAE Stock Holding History

Legato Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,194	Closed	-$1.06M	–	797
2025 Q4	$1.06M	Buy	+13,194	New	+$886K	0.09%	343
2024 Q3	–	Sell	-8,088	Closed	-$669K	–	595
2024 Q2	$669K	Buy	8,088 +614	+8%	+$54K	0.09%	363
2024 Q1	$638K	Buy	7,474 +3,766	+102%	+$296K	0.08%	384
2023 Q4	$317K	Sell	3,708 -5,381	-59%	-$465K	0.04%	489
2023 Q3	$814K	Buy	9,089 +3,957	+77%	+$353K	0.12%	291
2023 Q2	$437K	Buy	5,132 +2,265	+79%	+$191K	0.06%	451
2023 Q1	$237K	Sell	2,867 -302	-10%	-$24.4K	0.04%	431
2022 Q4	$249K	Buy	+3,169	New	+$255K	0.05%	423
2018 Q1	–	Sell	-13,224	Closed	-$768K	–	160
2017 Q4	$768K	Hold	13,224	–	–	0.11%	170
2017 Q3	$593K	Hold	13,224	–	–	0.09%	190
2017 Q2	$522K	Buy	13,224 +11,888	+890%	+$488K	0.22%	119
2017 Q1	$54K	Hold	1,336	–	–	0.06%	63
2016 Q4	$53.7K	Buy	+1,336	New	+$50.4K	0.97%	48

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Legato Capital Management's HAE Position: Q1 2026 in Review

Legato Capital Management sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 13,194 shares — an estimated $1.06M sold.

Legato Capital Management first reported a position in HAE in Q4 2016 and held it in 13 quarters. The position peaked at $1.06M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Legato Capital Management reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
Legato Capital Management sold 13,194 Haemonetics shares in Q1 2026, an estimated $1.06M.
Legato Capital Management first reported a position in Haemonetics in Q4 2016 and held it in 13 quarters.
Legato Capital Management's Haemonetics position peaked at $1.06M in Q4 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.